Cohort studycited by the Tayebat archiveabstract only checked A-CHM-01 standard review
Heart damage after anthracycline chemotherapy is common in the first year
Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Overview
Cardinale D et al.. Circulation 2015 · PMID 25948538 · DOI 10.1161/CIRCULATIONAHA.114.013777
About 9 in 100 patients developed a measurable drop in heart pumping function, mostly within one year; most recovered fully or partly with heart medication.
Does the study support the specific claim? Yes · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Measure how often and when anthracyclines damage the heart.
- How was the study done?
Prospective cohort with repeated echocardiography.
- How many people, animals or samples were studied?
2,625 patients.
- What was actually found?
9% cardiotoxicity, 98% within the first year, dose-related.
- How large was the observed effect?
HR 1.09 per 50 mg/m2 doxorubicin.
- What do the results mean in everyday life?
Heart monitoring during and after anthracycline therapy is important.
- What are the study's limitations?
Single centre, no untreated group.
- What does it say about Elawady's specific claim?
Confirms the harm exists; does not weigh it against cancer-survival benefit.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That anthracyclines do more harm than good.
Scientific in-depth review
1. Full reference
- Authors
- Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM
- Journal
- Circulation
- Year
- 2015
- Identifier
- PMID 25948538 DOI 10.1161/CIRCULATIONAHA.114.013777
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Incidence, timing, correlates and reversibility of anthracycline cardiotoxicity.
3. Study design and population
- Study design
- Cohort study – Prospective single-cohort study with scheduled echocardiographic LVEF monitoring
- Population
Heterogeneous adult cohort receiving anthracycline-containing chemotherapy
- Country
not stated in abstract (single institution)
- Period
not stated in abstract; median follow-up 5.2 years
- Sample size
2625
- Inclusion and exclusion criteria
Patients receiving anthracycline-containing therapy; details not in abstract
4. Methods and endpoints
- Exposure / intervention
Anthracycline-containing chemotherapy (cumulative doxorubicin dose)
- Comparator
Internal (dose levels, LVEF)
- Endpoints
Cardiotoxicity (LVEF fall >10 points and <50%), recovery after heart-failure therapy
- Statistical methods
Multivariable hazard models
5. Actual results
- Results
Cardiotoxicity 9% (n=226); median 3.5 months after end of chemotherapy; 98% (n=221) within first year. Full recovery 11%, partial recovery 71% with heart-failure therapy. HR 1.37 (95% CI 1.33-1.42) per 1% lower end-of-chemotherapy LVEF; HR 1.09 (1.04-1.15) per 50 mg/m2 cumulative doxorubicin.
- Absolute risks
9% cumulative incidence of LVEF-defined cardiotoxicity over median 5.2 years
- Authors' conclusion
Most cardiotoxicity occurs within the first year, is dose-related, and early detection plus prompt heart-failure therapy allows substantial recovery.
6. Strengths
- Large prospective cohort
- Systematic LVEF surveillance schedule
- Long follow-up
7. Weaknesses
- Single centre; heterogeneous cancers
- No untreated comparison group
- LVEF-based definition captures subclinical changes
8. Risk of bias
- Orienting tool
- ROBINS-E
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Observational; outcome measurement systematic; confounding by cancer type/other cardiotoxic therapy possible.
9. Assessment of the statistical interpretation
Precise estimates (narrow CIs); describes incidence and dose-response, not net benefit of therapy.
10. Relevance to the specific claim
Supports that anthracycline cardiotoxicity is real and dose-dependent.
11. Independent contrary findings
Recovery under heart-failure therapy (same study); cardio-oncology surveillance reduces the impact.
12. Transferability to Germany and Europe
High: anthracyclines are standard in Europe and Egypt; surveillance practice varies.
13. Overall methodological judgement
Solid descriptive cohort; correctly cited for the incidence figures, incomplete regarding recovery.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | high |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | essentially correct but incomplete |
14. Open questions
Long-term outcomes of partially recovered patients.
15. Linked fact checks
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Cardinale et al. followed 2,625 anthracycline-treated patients; 9% developed cardiotoxicity, 98% of it within the first year.
- A. What was actually studied?
Incidence and course of LVEF-defined cardiotoxicity under surveillance.
- B. What did the authors find?
9% incidence, mostly early, dose-related; most cases recovered fully or partly with heart-failure therapy.
- C. What conclusions do the authors themselves draw?
Early detection and prompt therapy are crucial for recovery.
- D. What does the archive derive from it?
Cited as evidence of chronic cardiotoxicity.
- E. Is this derivation scientifically justified?
Numbers are reported correctly. The archive omits that 82% of affected patients recovered fully or partly with treatment, which the authors emphasise.
- Adequacy of the interpretation (by the archive)
- essentially correct but incomplete